Evaluation of the Optimal Dose of GnRH Agonist for Triggering Final Oocyte Maturation in High Risk OHSS Patients
NCT ID: NCT01973842
Last Updated: 2016-02-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
90 participants
INTERVENTIONAL
2014-02-28
2016-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Final Oocyte Maturation Via Administration of GnRH Agonists Followed By Luteal Support With hCG
NCT01638026
Ovarian Stimulation Using Recombinant Follicle-stimulating Hormone (FSH) and Gonadotrophin Releasing Hormone (GnRH) Agonist in Alternate Days
NCT01468441
Can GnRH Agonist Trigger Prevent Ovarian Hyperstimulation Syndrome?
NCT01714648
Long Acting FSH Plus Antagonist Versus Daily FSH Plus Antagonist Versus Short Agonist Protocol in Poor Responders Undergoing IVF
NCT02070198
Endometrial Receptivity After GnRH Agonist Triggering
NCT01500863
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Secondary outcomes will include: number of oocytes retrieved, oocyte recovery rate (number of oocytes retrieved/ number of follicles \>11mm in diameter on the day of triggering), fertilization rates and OHSS occurrence.
Serum LH, FSH, E2, PRG levels will be assessed at 8-36 hours following agonist administration and on days 3-4-7-10 after triggering final oocyte maturation.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
0.2 mg triptorelin
0.2 mg triptorelin compared with 0.1 mg triptorelin and 0.4 mg triptorelin
0.2 mg triptorelin
0.1 mg triptorelin
0.1 mg triptorelin compared with 0.2 mg triptorelin and 0.4 mg triptorelin
0.1 mg triptorelin
0.4 mg triptorelin
0.4 mg triptorelin compared with 0.1 mg triptorelin and 0.2 mg triptorelin
0.4 mg triptorelin
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
0.1 mg triptorelin
0.2 mg triptorelin
0.4 mg triptorelin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Anticipated high ovarian response
Exclusion Criteria
* One ovary
20 Years
40 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eugonia IVF Unit, Athens, Greece
OTHER
Aristotle University Of Thessaloniki
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
E.M. Kolibianakis
Ass Professor in Obstetrics - Gynecology and Assisted Reproduction
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Efstratios Kolibianakis, MD, MSc, PhD
Role: PRINCIPAL_INVESTIGATOR
Unit of Human Reproduction, 1st Dept of Obstetrics and Gynaecology, Medical School, Aristotle University of Thessaloniki Thessaloniki, Greece
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Eugonia IVF Unit
Athens, , Greece
Unit of Human Reproduction, 1st Dept of Obstetrics and Gynaecology, Medical School, Aristotle University of Thessaloniki
Thessaloniki, , Greece
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Agonist triggering dose
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.